Earnings Scheduled For August 30, 2022
Companies Reporting Before The Bell
• Photronics (NASDAQ:PLAB) is likely to report quarterly earnings at $0.50 per share on revenue of $210.00 million.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's trading, 62 companies set new 52-week lows.
Bed Bath & Beyond, America’s Car-Mart And Some Other Big Stocks Moving Lower On Thursday
Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC Ventures, which suggested the firm proposed to sell 7.78 million common shares and certain call options. Additionally, Wedbush downgraded the stock to Underperform.
This Analyst Cuts I-Mab’s Price Target By 43%
I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents.
Needham Maintains Buy Rating for I-MAB: Here’s What You Need To Know
Needham has decided to maintain its Buy rating of I-MAB (NASDAQ:IMAB) and lower its price target from $72.00 to $41.00.
Shares of I-MAB are trading down 15.43% over the last 24 hours, at $6.74 per share.
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle platform.
AbbVie Calls Off Early-Stage Trial For I-Mab’s CD47-Targeted Blood Cancer Candidate
I-Mab (NASDAQ:IMAB) disclosed in an SEC filing that AbbVie Inc (NYSE:ABBV) would discontinue the global Phase 1b study of lemzoparlimab combination therapy with…
Needham Maintains Buy on I-MAB, Lowers Price Target to $41
Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $72 to $41.